Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Monopar Therapeutics Inc

MNPR
Current price
16.66 USD -0.74 USD (-4.25%)
Last closed 16.88 USD
ISIN US61023L1089
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 89 089 256 USD
Yield for 12 month +967.61 %
1Y
3Y
5Y
10Y
15Y
MNPR
21.11.2021 - 28.11.2021

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC. Address: 1000 Skokie Boulevard, Wilmette, IL, United States, 60091

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

18 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

Current Quarter

Last Quarter

Key Figures MNPR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA
Operating Margin TTM
PE Ratio
Return On Assets TTM -53.45 %
PEG Ratio
Return On Equity TTM -102.31 %
Wall Street Target Price 18 USD
Revenue TTM
Book Value 1.88 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -2.3 USD
Diluted Eps TTM -2.3 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics MNPR

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History MNPR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:5
Payout Ratio
Last Split Date 13.08.2024
Dividend Date

Stock Valuation MNPR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -2.4233
Price Book MRQ 14.628

Financials MNPR

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators MNPR

For 52 weeks

1.37 USD 38.5 USD
50 Day MA 7.55 USD
Shares Short Prior Month 112 378
200 Day MA 4.4 USD
Short Ratio 0.15
Shares Short 49 852
Short Percent 10.22 %